AIxMed, an early-stage smart cytology company at the intersection of artificial intelligence (AI) and medicine, announced that it has raised $2.75 million in a SAFE round of financing from existing investors to further develop its digital cytology platform.

AIxMed helps Pathologists digitize cytology samples in minutes and extract clinical insights in seconds to improve patient diagnosis and care. Their first application, AIxURO, is an AI-assisted urine cytology imaging and reporting software package for bladder cancer diagnosis and surveillance based on The Paris System (TPS).